Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon
- 3 July 2019
- journal article
- research article
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 28 (2) , 305-314
Abstract
Purpose: To compare the efficacy and safety of infliximab and interferon in patients with refractory Behçet uveitis. Methods: Medical records of 20 patients treated with infliximab (IFX) and 33 patients treated with interferon (IFN) were retrospectively analyzed by evaluating the number of uveitis attacks, visual acuity and ocular inflammation at 6 and 12 months after initiation of treatment. Results: Mean duration of treatment was 22 ± 18 months in IFX group and 30.3 ± 22.5 months in IFN group. Sixteen patients of IFX group (80%) and 28 patients of IFN group (85%) achieved remission. In both groups, the mean best-corrected visual acuity and all inflammatory parameters improved. In terms of these parameters, there was no significant difference between the two groups. Conclusion: Infliximab and interferon improve control of ocular inflammation and efficiently decrease the relapse rate. Our results determined no significant difference between two agents in controlling intraocular inflammation.Keywords
This publication has 46 references indexed in Scilit:
- Long‐term remission after cessation of interferon‐α treatment in patients with severe uveitis due to Behçet's diseaseArthritis & Rheumatism, 2010
- Safety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet's Uveitis Refractory to Conventional TreatmentsOphthalmology, 2010
- Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitisBritish Journal of Ophthalmology, 2009
- Ocular Inflammation in Behçet Disease: Incidence of Ocular Complications and of Loss of Visual AcuityAmerican Journal of Ophthalmology, 2008
- Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patientsBritish Journal of Ophthalmology, 2006
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003
- Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's diseaseJournal of Internal Medicine, 1998
- Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot studyBritish Journal of Ophthalmology, 1998
- The neglected role of type I interferon in the T-cell response: implications for its clinical useImmunology Today, 1996
- Interferon therapy for Behçet's diseaseJournal of the American Academy of Dermatology, 1994